Evidence map›Paper›PMID 22119924›Full record

ArticleVaccine2012

Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine.

Jennie S Lavine, Ottar N Bjørnstad, Birgitte Freiesleben de Blasio, Jann Storsaeter

Abstract read
In one paragraph

Article in Vaccine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Pertussis vaccines, epidemiology and evolution.Nature reviews. Microbiology · 2024
    Review
  6. Evolution of Bordetella pertussis in the acellular vaccine era in Norway, 1996 to 2019.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Systematic review and meta-analysis of pertussis epidemiology in Latin America and the Caribbean: 1980-2015.Revista panamericana de salud publica = Pan American journal of public health · 2017
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Jennie S LavineCenter for Infectious Disease Dynamics, 501 ASI Bldg, Penn State University, University Park, PA 16802, USA. jennie.lavine@gmail.com
Ottar N Bjørnstad
Birgitte Freiesleben de Blasio
Jann Storsaeter
Norwegian Institute of Public Health · NOFogarty International Center · USNational Institutes of Health · US

Funding

Evolution of the Bordetellae from Commensals to PathogensR01GM083113 · NIGMS · PENNSYLVANIA STATE UNIVERSITY, THE · PI HARVILL, ERIC T · 2008 to 2011
$2.1M
NIGMS NIH HHS R01 GM083113
6 · The paper itself

Abstract

backgroundPertussis incidence has been increasing for the past two decades in Norway, as in much of the highly vaccinated world. The greatest increase is in teenagers, although the most severe cases occur in infants. A teenage booster is recommended globally, largely with the aim of reducing infant incidence. However few countries have implemented the booster, and almost no data have been published on its utility in preventing infant cases. We aim to assess the duration of vaccine-induced immunity, and the possibility for a teenage-booster vaccine to protect infants in Norway. METHODS AND

findingsWe used a unique data set that merged case reports with a national vaccine registry from Norway, 1996-2010, to assess age- and cohort-specific hazards of infection. We also developed and implemented a likelihood-based method for estimating the duration of immunity, taking into account age-contact data relevant for pertussis transmission. The risk of infection in thirteen-year olds increased nearly four-fold, however the hazard in infants did not significantly change. The seasonality of cases in pre-school-aged children differed from that of school-aged children. The introduction of a childhood booster vaccine provided indirect protection for unvaccinated members of the cohort, but little protection to neighboring cohorts. Additionally, we found evidence for increasingly rapid infection after three doses of vaccine, potentially caused by significant and heterogeneous loss of immunity. An estimated 15% of vaccinated individuals lost their immunity within five years after vaccination.

conclusionsImmunity induced by the acellular pertussis vaccine prevents both disease and transmission, but is short-lived and heterogeneous. The age-mixing patterns lead to little contact between teenagers and infants. Therefore, while a teenage booster vaccine campaign would likely provide strong protection for cohorts of teenagers, it would provide little protection for infants.

Indexed as

AdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleHumansImmunization, SecondaryIncidenceInfantInfant, NewbornMaleMiddle AgedNorwayPertussis VaccinePertussis VaccineVaccines, Acellular

Identifiers

PMID22119924
PMCPMC3246080
OpenAlexW2148612494

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.